| Methods and compositions for dosing of allogeneic chimeric antigen receptor t … |
2023-10-10 |
2024-2-08 |
|
| In vitro method for inhibiting hhv-6 infection |
2023-8-16 |
2024-2-22 |
|
| Chimeric cytokine receptors bearing a pd-1 ectodomain |
2023-8-03 |
2024-1-18 |
|
| Engineered cells with reduced gene expression to mitigate immune cell … |
2023-7-28 |
2024-2-08 |
|
| Anti-talen antibodies and uses thereof |
2023-7-18 |
2024-1-04 |
|
| Methods for detecting genomic abnormalities in cells |
2023-6-09 |
2023-12-14 |
|
| Methods for donor cell analysis |
2023-4-28 |
2023-12-21 |
|
| Dll3 targeting chimeric antigen receptors and binding agents |
2023-4-27 |
2023-9-14 |
|
| Chimeric switch receptors for the conversion of immunesuppressive signals to … |
2023-3-29 |
2023-11-02 |
|
| Improved T cell compositions and methods |
2023-3-28 |
2023-6-22 |
|
| bcma car t cells with enhanced activities |
2022-8-19 |
2022-8-30 |
|
| Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car … |
2022-6-15 |
2023-12-14 |
|
| Selective targeting of host cd70+ alloreactive cells to extend allogeneic CAR T … |
2022-6-15 |
2024-2-06 |
|
| Plastic jacket for vial labeling systems |
2022-4-11 |
2022-6-01 |
|
| Modified caspase-9 polypeptides and methods of use thereof |
2022-4-08 |
2022-7-28 |
|
| Fasl expression and fasr gene knockout to protect therapeutic cells from … |
2022-3-04 |
2024-1-10 |
|
| Methods of preparing t cells for t cell therapy |
2022-3-02 |
2022-5-01 |
|
| Chimeric cytokine receptors comprising tgf beta binding domains |
2022-2-27 |
2022-4-01 |
|
| Formulations and processes for car t cell drug products |
2022-2-03 |
2023-8-01 |
|
| Knocking down or knocking out one or more of TAP2, NLRC5, β m, TRAC, RFX5, … |
2022-1-28 |
2023-11-17 |
|
| Method for transducing immune cells |
2022-1-28 |
2023-9-15 |
|
| Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and … |
2022-1-28 |
2022-8-04 |
|
| Methods for transducing immune cells |
2022-1-28 |
2023-7-06 |
|
| Protease activated CD45 gated CAR |
2021-12-21 |
2023-9-15 |
|
| Protease-activating cd45-gate car |
2021-12-21 |
2023-10-25 |
|
| Methods and reagents for characterizing car t cells for therapies |
2021-12-14 |
2022-6-23 |
|
| Methods and reagents for characterizing CAR T cells for treatment |
2021-12-14 |
2023-8-25 |
|
| Inhibitory chimeric antigen receptors |
2021-11-19 |
2022-3-08 |
|
| Methods of manufacturing allogeneic car t cells |
2021-10-25 |
2021-12-01 |
|
| Rituximab-resistant chimeric antigen receptors and their uses |
2021-10-22 |
2021-10-29 |
|
| Antibodies against 4g7-derived chimeric antigen receptors |
2021-10-17 |
2021-12-01 |
|
| Methods for enhancing tcrαβ+ cell depletion efficiency |
2021-10-03 |
2021-10-31 |
|
| Constitutively active chimeric cytokine receptors |
2021-8-29 |
2021-10-31 |
|
| Chimeric antigen receptors with enhanced signaling and activities and uses … |
2021-7-21 |
2023-2-09 |
|
| Chimeric antigen receptors targeting b-cell maturation antigen and methods of … |
2021-5-12 |
2021-6-30 |
|
| BCMA CAR T CELLS WITH ENHANCED ACTIVITIES |
2021-2-24 |
2022-6-01 |
|
| Combination therapies of chimeric antigen receptors targeting b-cell maturation … |
2021-1-15 |
2023-4-13 |
|
| POLYTHERAPIES COMPOSED BY CHIMERIC ANTIGEN RECEPTORS WHICH ACT SELECTIVELY ON … |
2021-1-15 |
2022-4-13 |
|
| Inducible chimeric cytokine receptors |
2020-8-20 |
2020-10-29 |
|
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND THEIR USES |
2020-4-24 |
2022-1-05 |
|
| CHEMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 |
2020-2-27 |
2021-9-22 |
|
| RECEPTORS OF CHEMERIC ANTIGENS TARGETING THE MATURING ANTIGEN OF B CELLS AND … |
2019-11-26 |
2021-7-14 |
|
| Methods and compositions for dosing of allogeneic chimeric antigen receptor T … |
2018-10-30 |
2023-11-24 |
|
| METHODS AND COMPOSITIONS FOR DOSING T LYMPHOCYTES WITH ALLOGEN CHIMERICAL … |
2018-10-30 |
2020-6-17 |
|
| Mab-driven chimeric antigen receptor systems for sorting/depleting engineered … |
2017-6-20 |
2022-1-01 |
|
| Egfrviii specific chimeric antigen receptors for cancer immunotherapy |
2015-7-29 |
2016-2-04 |
|
| Procédé in vitro d'inhibition d'une infection par hhv-6 |
2023-8-16 |
2024-2-22 |
|